<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028209</url>
  </required_header>
  <id_info>
    <org_study_id>PBR06 001</org_study_id>
    <nct_id>NCT01028209</nct_id>
  </id_info>
  <brief_title>Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions</brief_title>
  <acronym>PBR06</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <brief_summary>
    <textblock>
      The underlying goal of this study is to assess [18F] PBR06 PET imaging as a tool to detect
      microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and
      Multiple Sclerosis (MS) research participants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of AD, PD and MS research participants.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Parkinson Disease</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Assess [18F] PBR06 and PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F] PBR06</intervention_name>
    <description>Subjects will be injected with 5mCi, not to exceed &gt;10% of 5mCI, of [18F]PBR06, followed by PET imaging.</description>
    <arm_group_label>Assess [18F] PBR06 and PET imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The following criteria will be met for inclusion of AD subjects in this study:

               -  The participant is 50 years or older.

               -  Written informed consent is obtained.

               -  Participants have a clinical diagnosis of probable Alzheimer's disease based on
                  National Institute of Neurological and Communicative Disorders and
                  Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)
                  criteria.

               -  Clinical Dementia Rating Scale score ≤ 2.

               -  Modified Hachinski Ischemia Scale score of ≤ 4.

               -  For females, non-child bearing potential or a negative urine or blood pregnancy
                  test on day of [18F]-PBR06 injection.

          -  The following criteria will be met for inclusion of PD subjects in this study:

               -  The participant is 30 years or older.

               -  Written informed consent is obtained.

               -  Participants have a clinical diagnosis of Parkinson disease (at least two of the
                  three cardinal symptoms: resting tremor, rigidity, bradykinesia).

               -  Hoehn and Yahr ≤4.

               -  For females, non-child bearing potential or a negative urine or blood pregnancy
                  test on day of [18F]-PBR06 injection.

          -  The following criteria will be met for inclusion of MS subjects in this study:

               -  The participant is 18 years or older.

               -  Written informed consent is obtained.

               -  Participants have a clinical diagnosis of Multiple Sclerosis (per the 2005
                  Revised McDonald Criteria; Polman, et al., 2005).

               -  Kurtzke Expanded Disability Status Scale (EDSS) ≤ 7.5.

               -  For females, non-child bearing potential or a negative urine or blood pregnancy
                  test on day of [18F]-PBR06 injection

          -  The following criteria will be met for inclusion of healthy control subjects in this
             study:

               -  The participant is 18 years or older.

               -  Written informed consent is obtained.

               -  Negative history of neurological or psychiatric illness based on evaluation by a
                  research physician.

               -  Clinical Dementia Rating score = 0.

               -  For females, non-child bearing potential a negative urine or blood pregnancy test
                  on day of [18F]-PBR06 injection.

        Exclusion Criteria:

          -  Alzheimer's subjects will be excluded from participation for the following reasons:

               -  The subject has a history of significant cerebrovascular disease.

               -  The subject has a clinically significant abnormal laboratory value and/or
                  clinically significant unstable medical or psychiatric illness

               -  The subject has evidence of clinically significant gastrointestinal,
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.

               -  Pregnancy

          -  Parkinson's subjects will be excluded from participation for the following reasons:

               -  The subject has a clinically significant abnormal laboratory value and/or
                  clinically significant unstable medical or psychiatric illness

               -  The subject has evidence of clinically significant gastrointestinal,
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.

               -  Pregnancy

          -  MS subjects will be excluded from participation for the following reasons:

               -  The subject has a clinically significant abnormal laboratory value and/or
                  clinically significant unstable medical or psychiatric illness

               -  The subject has evidence of clinically significant gastrointestinal,
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.

               -  Pregnancy

          -  Healthy control subjects will be excluded from participation for the following
             reasons:

               -  The subject has a clinically significant abnormal laboratory value and/or
                  clinically significant unstable medical or psychiatric illness.

               -  The subject has evidence of clinically significant gastrointestinal,
                  cardiovascular, hepatic, renal, hematological, neoplastic, endocrine,
                  neurological, immunodeficiency, pulmonary, or other disorder or disease.

               -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>October 8, 2010</last_update_submitted>
  <last_update_submitted_qc>October 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Danna Jennings, MD / Principal Investigator</name_title>
    <organization>Institute for Neurodegenerative Disorders</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

